What is ultrasound Fibroscan?

Fibroscan is an innovative ultrasound technique used to quantitatively assess the degree of cirrhosis by measuring liver stiffness (Liver Stiffness Measurement: LSM). It can also evaluate liver steatosis based on the "Controlled Attenuation Parameter" (CAP), which is calculated from the ultrasonic signal during the stiffness measurement.

The Super Fibroscan offers simultaneous measurement of fibrosis and fatty liver levels, providing several notable advantages: it is non-invasive (causing no pain to the patient), fast, accurate (equivalent to a liver biopsy), and cost-effective.

Technological foundation of ultrasound Fibroscan

VCTEtm technology - Quantifying liver fibrosis

• Vibration Controlled Transient Elastography (VCTETM) is used to control the frequency of the shear wave at a fixed frequency of 50Hz.
• The investigation volume area (ROI) is approximately 3 cm3 (around 100 times the size of a biopsy sample).
• It can measure liver stiffness ranging from 2.5 to 75 kPa.
• Results are based on the median value of 10 measurements, ensuring high repeatability and accuracy.

CAPtm technology - Quantifying liver steatosis

• CAP (dB/m) technology measures signal attenuation in the tissue, providing an index for comparing and evaluating the fatty liver condition.
• CAP is performed in conjunction with VCTE at a single examination location.
• Results are based on the median value of 10 measurements, ensuring high repeatability and accuracy.

SmartExam - Expanding the scope of examination

SmartExam utilizes a new processing method that continuously captures the CAP signal throughout the measurement process.

Ultrasound Fibroscan measurement results

Research and proven clinical value

• CE - 2003
• ISO 13485 - 2005
• FDA - April 2013
• Recommended in diagnostic and treatment guidelines by the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL).
• Endorsed by the Ministry of Health of Vietnam (VGB 2019 & VGC 2021).
• Recognized by the World Federation for Ultrasound in Medicine and Biology (WFUMB 2018) and the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB 2017).
• The application value of Fibroscan has been published in over 3,500 peer-reviewed publications and more than 160 international guidelines.

Fibroscan ultrasound is considered the preferred method for classifying the level of liver fibrosis according to the Ministry of Health's Guideline on the Diagnosis and Treatment of Hepatitis C Virus (No. 2065/QD-BYT) issued on April 26, 2021.